Blade Therapeutics is a biopharmaceutical company that is focused on developing cutting-edge treatments for fibrotic and neurodegenerative diseases that impact millions of people worldwide.
The company specializes in novel biological pathways, such as autotaxin/LPA and calpain biology, which are foundational to cell- and tissue-damage responses associated with fibrotic and neurodegenerative diseases. This focused approach offers the potential to produce disease-modifying, life-saving therapies.
Since its founding in 2015, the company has assembled critical leadership expertise and a world-class network of scientific, pharmaceutical, and clinical advisors to enable efficient and successful drug development. Blade Therapeutics is advancing a differentiated pipeline of oral, small-molecule therapies, including a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains, which are designed for the potential treatment of lung, liver and cardiac fibrosis, or neurodegenerative diseases.
“I first met the OneVentures team in July 2018. They quickly impressed me with their broad knowledge and capabilities. Shortly afterwards, they led our Series C round. It has been a pleasure to build the company with the support of Paul, Sarah, Michelle, and Gabriel, and their LP’s over the past 3 years. The fund is a true value add investor with deep connections to academic institutions and opinion leaders.”
